NAT2 and colorectal carcinoma: The number of patients standing to benefit from treatment with APA will depend on (1) the fraction of the CRC patient population that has a targetable NAT2 intermediate acetylator phenotype (i.e. harbor a rapid and a slow NAT2 allele where the slow allele cannot process APA), and (2) the fraction of CRCs that lose their rapid NAT2 allele.